Johnson & Johnson acquires for $14.6 billion! Intra-Cellular Therapies stock surges nearly 38% in pre-market trading

Wallstreetcn
2025.01.13 12:55
portai
I'm PortAI, I can summarize articles.

Johnson & Johnson acquired Intra-Cellular Therapies for $14.6 billion, making it the largest biotechnology merger and acquisition deal since 2023, and the first biopharmaceutical merger and acquisition exceeding $10 billion in 2024. Intra-Cellular's stock price rose nearly 38% in pre-market trading, while Johnson & Johnson's stock price remained unchanged

Johnson & Johnson is acquiring Intra-Cellular Therapies for $14.6 billion, marking the largest biotechnology merger since 2023 and the first biopharmaceutical merger exceeding $10 billion since 2024. Intra-Cellular's stock surged nearly 38% in pre-market trading, while Johnson & Johnson's stock remained flat.

Risk Warning and Disclaimer

The market carries risks, and investment should be approached with caution. This article does not constitute personal investment advice and does not take into account the specific investment objectives, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article align with their specific circumstances. Investment based on this is at one's own risk

Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.